Agile at scale : a summary of the 8th International Workshop on Large-Scale Agile Development

The Large-Scale Agile Development workshop explored the main research challenges in large-scale software development. We considered multi-site organisations with large-scale projects that include a large number of teams adopting agile methods. Such topics include inter-team coordination, knowledge sharing, large project organisation, agile transformation, agile teamwork quality, project models that facilitate several self-organising teams, and practices for scaling agile methods. We accepted five full research papers, which are included in this volume. The accepted papers report empirical research studies using surveys, observations and case studies. Also, an interactive online discussion session was conducted to compare the two approaches, SAFe and Spotify. The workshop participants, which were around a hundred people, joined this discussion to compare the two approaches and suggest some future research questions about the hybridisation of SAFe and Spotify. This workshop summary contributes as a current snapshot of research along with some results from an interactive discussion about SAFe and Spotify

Formulas in inverse and ill-posed problems

The Inverse and Ill-Posed Problems Series is a series of monographs publishing postgraduate level information on inverse and ill-posed problems for an international readership of professional scientists and researchers. The series aims to publish works which involve both theory and applications in, e.g., physics, medicine, geophysics, acoustics, electrodynamics, tomography, and ecology

Structure optimization of a new class of PPARγ antagonists

Peroxisome proliferator-activated receptor gamma (PPARγ) modulators have found wide application for the treatment of cancers, metabolic disorders and inflammatory diseases. Contrary to PPARγ agonists, PPARγ antagonists have been much less studied and although they have shown immunomodulatory effects, there is still no therapeutically useful PPARγ antagonist on the market. In contrast to non-competitive, irreversible inhibition caused by 2-chloro-5-nitrobenzanilide (GW9662), the recently described (E)-2-(5-((4-methoxy-2-(trifluoromethyl)quinolin-6-yl)methoxy)-2-((4-(trifluoromethyl)benzyl)oxy)-benzylidene)-hexanoic acid (MTTB, T-10017) is a promising prototype for a new class of PPARγ antagonists. It exhibits competitive antagonism against rosiglitazone mediated activation of PPARγ ligand binding domain (PPARγLBD) in a transactivation assay in HEK293T cells with an IC50 of 4.3 µM against 1 µM rosiglitazone. The aim of this study was to investigate the structure-activity relationships (SAR) of the MTTB scaffold focusing on improving its physicochemical properties. Through this optimization, 34 new derivatives were prepared and characterized. Two new potent compounds (T-10075 and T-10106) with much improved drug-like properties and promising pharmacokinetic profile were identified